Mirum tees up Livmarli label expansion on Phase III liver disease study success
Mirum Pharmaceuticals' Livmarli showed success in a Phase III trial for treating itch in rare liver diseases, meeting all endpoints. The drug reduced itch scores and blood bile acid levels significantly. Mirum plans to submit an sNDA in 2027, potentially expanding Livmarli's label. Analysts project $876m in sales by 2032. Livmarli is currently FDA-approved for two rare liver conditions.
How this was made
The 30-second read
Why it matters
A successful Phase III readout plus a stated sNDA submission plan is a direct catalyst for Mirum’s regulatory and commercial outlook. If approved, Livmarli could become the first therapy for biliary atresia, expanding the addressable patient population and strengthening the product’s long-term growth narrative.
Market read
Traders may reprice Mirum’s probability-weighted value of Livmarli’s label expansion after pivotal Phase III success and a concrete sNDA timeline.
What to watch
The article does not quantify regulatory review milestones, manufacturing readiness, or payer/market access dynamics for biliary atresia, which can materially affect realized sales despite clinical success.
Background
Livmarli (maralixibat) is already FDA-approved for itch in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). The EXPAND Phase III study evaluates itch reduction across ultra-rare liver diseases, including a large biliary atresia subgroup.
Ticker impact
Mirum says Livmarli met primary and five secondary endpoints in Phase III EXPAND for itch across ultra-rare liver diseases, including biliary atresia, and plans an sNDA in 1H 2027.
Likely upward bias as traders price in improved probability of an sNDA filing and potential new indication approval pathway.
The article reports Phase III success with endpoint details and a concrete regulatory next step (sNDA in 1H 2027), which is directly tied to Mirum’s core asset and future revenue optionality.
Market effects
Strengthens sentiment for IBAT-targeting cholestatic itch programs and ultra-rare liver disease development, potentially improving perceived competitive positioning for similar mechanisms.
Primarily US biotech sentiment, with potential spillover to small-cap healthcare risk appetite.
Could influence global rare-disease investor focus on regulatory pathways for pediatric cholestatic disorders.
Counterpoint
Even with positive Phase III results, label expansion timing and ultimate approval remain uncertain, and the market may already be positioned for incremental data from this program.
Key entities
- companyMirum Pharmaceuticals
Company developing Livmarli and planning an sNDA to expand the label based on Phase III EXPAND results.
- drugLivmarli (maralixibat)
IBAT inhibitor therapy evaluated for itch reduction in ultra-rare liver diseases, including biliary atresia.
- clinical_trialEXPAND study (NCT06553768)
Placebo-controlled Phase III trial reporting primary and five secondary endpoint success, including biliary atresia endpoints.
- indicationBiliary atresia
Ultra-rare, potentially life-threatening pediatric liver disease with no approved therapies cited in the article.
